<DOC>
	<DOCNO>NCT01447654</DOCNO>
	<brief_summary>Objective The objective study assess structural functional cardiac effect treatment losartan patient hypertrophic cardiomyopathy ( HCM ) . Design The study randomize , placebo‐controlled , double‐blinded trial . The follow‐up period 12 month . 130 patient HCM include predefined subgroup . Genotype positive relative borderline hypertrophy ( &gt; 13 mm ) also include . Data individual borderline hypertrophy analyse separately rest cohort . Primary outcome Ventricular hypertrophy assess leave ventricular mass maximal wall thickness .</brief_summary>
	<brief_title>Inhibition Renin Angiotensin System With Losartan Patients With Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Hypertrophic cardiomyopathy &gt; 18 year Sinus rhythm EF &lt; 50 % Treatment RASinhibitor Contraindications losartan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hypertrophic cardiomyopathy</keyword>
	<keyword>Hypertrophic obstructive cardiomyopathy</keyword>
	<keyword>Hypertrophy</keyword>
	<keyword>Losartan</keyword>
	<keyword>Angiotensin II receptor antagonist</keyword>
</DOC>